Bibliography
- BAIER G, TELFORD D, GIAMPA L et al.: Molecular cloning and characterization of PKCθ, a human novel member of the PKC gene family expressed predominantly in hematopoietic cells. J. Bio. Chem. (1993) 268:4997-5004.
- CHANG JD, XU Y, RAYCHOWDHURY MK, WARE JA: Molecular cloning and expression of a cDNA encoding a novel isoenzyme of protein kinase C (nPKC). J. Bio. Chem. (1993) 268:14208-14214.
- ALTMAN A, VILLALBA M: Protein kinase C-θ (PKCθ): it is all about location, location, location. Immunol. Rev. (2003) 192:52-53.
- SEDWICK C: Perspective on PKCθ in T cell activation. Mol. Immunol. (2004) 41:765-686.
- LI Y, SOOS TJ, LI X et al.: Protein kinase C-θ inhibits insulin signaling by phosphorylating IRSI at Ser1101. J. Bio. Chem. (2004) 279:45304-45307.
- Lilly delivers promising update to wall street on strategic priorities, pipeline progress and earnings guidance. Eli Lilly & Co. Press Release (2006) December 7.
- GOTLIB J et al.: Phase II trial of the tyrosine kinase inhibitor PKC412 in advanced systemic mastocytosis: preliminary results. Blood (2006) 108:11.
- Investigational treatment ruboxistaurin demonstrated promise in reducing the occurrence of vision loss caused by diabetic retinopathy. Eli Lilly & Co. Press Release (2006) June 11.
- CYWIN CL, DAHMANN G, PROKOPOWICZ AS III et al.: Discovery of potent and selective PKC-θ inhibitors. Bioorg. Med. Chem. Lett. (2007) 17:225-230.
- SALEK-ARDAKANI S, SOT, HALTEMAN BS, ALTMAN A, CROFT M: Protein kinase C-θ controls TH1 cells in experimental autoimmune encephalomyelitis. J. Immunology. (2005) 175:7635-7641.
- TAN S-L, ZHAO J, BI C et al.: Resistance to experimental autoimmune encephalomyelitis and impaired IL-17 production in protein kinase C-θ-deficient mice. J. Immunology. (2006) 176:2872-2879.
- XU Z-B, CHAUDHARY D, OLLAND S et al.: Catalytic domain of crystal structure of protein kinase C-θ. J. Bio Chem. (2004) 279:50410-50409.
Patents
- BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.: US20040242613 (2004).
- BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.: US2006025433 (2006).
- BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.: US20060217417 (2006).
- AMGEN, INC.: US20050182072 (2005).
- MILLENNIUM PHARMACEUTICALS, INC.: US20060040968 (2006).
- NOVARTIS AG: WO2005039549 (2005).